Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

217 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study.
Lapucci C, Frau J, Cocco E, Coghe G, Petracca M, Lanzillo R, Brescia Morra V, Nicoletti CG, Landi D, Marfia G, Vercellino M, Cavalla P, Bianco A, Mirabella M, Torri Clerici V, Tomas E, Ferrò MT, Grossi P, Nozzolillo A, Moiola L, Zaffaroni M, Ronzoni M, Pinardi F, Novi G, Cellerino M, Uccelli A, Inglese M. Lapucci C, et al. Among authors: frau j. Mult Scler. 2024 Aug;30(9):1151-1162. doi: 10.1177/13524585241266509. Epub 2024 Aug 14. Mult Scler. 2024. PMID: 39143825
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
Zecca C, Bovis F, Novi G, Capobianco M, Lanzillo R, Frau J, Repice AM, Hakiki B, Realmuto S, Bonavita S, Curti E, Brambilla L, Mataluni G, Cavalla P, Di Sapio A, Signoriello E, Barone S, Maniscalco GT, Maietta I, Maraffi I, Boffa G, Malucchi S, Nozzolillo A, Coghe G, Mechi C, Salemi G, Gallo A, Sacco R, Cellerino M, Malentacchi M, De Angelis M, Lorefice L, Magnani E, Prestipino E, Sperli F, Brescia Morra V, Fenu G, Barilaro A, Abbadessa G, Signori A, Granella F, Amato MP, Uccelli A, Gobbi C, Sormani MP. Zecca C, et al. Among authors: frau j. Mult Scler. 2020 Oct;26(12):1519-1531. doi: 10.1177/1352458519872889. Epub 2019 Oct 1. Mult Scler. 2020. PMID: 31573386
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy.
Signoriello E, Lus G, Bonavita S, Lanzillo R, Saccà F, Landi D, Frau J, Baroncini D, Zaffaroni M, Maniscalco GT, Curti E, Sartori A, Cepparulo S, Marfia GA, Nicoletti CG, Carotenuto A, Nociti V, Caleri F, Sormani MP, Signori A. Signoriello E, et al. Among authors: frau j. Mult Scler. 2022 Jan;28(1):93-101. doi: 10.1177/13524585211005657. Epub 2021 Apr 15. Mult Scler. 2022. PMID: 33855897
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study.
Sormani MP, Schiavetti I, Landi D, Carmisciano L, De Rossi N, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Brescia Morra V, Trojano M, Tedeschi G, Comi G, Battaglia MA, Patti F, Fragoso YD, Sen S, Siva A, Furlan R, Salvetti M; MuSC-19 Study Group. Sormani MP, et al. Mult Scler. 2022 Jun;28(7):1034-1040. doi: 10.1177/13524585211035318. Epub 2021 Jul 30. Mult Scler. 2022. PMID: 34328824
Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy.
Lorefice L, Fenu G, Sardu C, Frau J, Coghe G, Costa G, Schirru L, Secci MA, Sechi V, Barracciu MA, Marrosu MG, Cocco E. Lorefice L, et al. Among authors: frau j. Mult Scler. 2019 Jan;25(1):23-30. doi: 10.1177/1352458517739989. Epub 2017 Nov 7. Mult Scler. 2019. PMID: 29111883
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study.
Saccà F, Lanzillo R, Signori A, Maniscalco GT, Signoriello E, Lo Fermo S, Repice A, Annovazzi P, Baroncini D, Clerico M, Binello E, Cerqua R, Mataluni G, Bonavita S, Lavorgna L, Zarbo IR, Laroni A, Rossi S, Pareja Gutierrez L, La Gioia S, Frigeni B, Barcella V, Frau J, Cocco E, Fenu G, Torri Clerici V, Sartori A, Rasia S, Cordioli C, Di Sapio A, Pontecorvo S, Grasso R, Barrilà C, Russo CV, Esposito S, Ippolito D, Bovis F, Gallo F, Sormani MP. Saccà F, et al. Among authors: frau j. Mult Scler. 2019 Aug;25(9):1263-1272. doi: 10.1177/1352458518790390. Epub 2018 Jul 25. Mult Scler. 2019. PMID: 30044207 Free article.
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders.
Novi G, Bovis F, Capobianco M, Frau J, Mataluni G, Curti E, Zuliani L, Cavalla P, Brambilla L, Annovazzi P, Repice AM, Lanzillo R, Esposito S, Benedetti L, Maietta I, Sica F, Buttari F, Malucchi S, Fenu G, Landi D, Bosa C, Realmuto S, Malentacchi M, Granella F, Signori A, Bonavita S, Uccelli A, Sormani MP; iMUST group. Novi G, et al. Among authors: frau j. Mult Scler Relat Disord. 2019 Nov;36:101430. doi: 10.1016/j.msard.2019.101430. Epub 2019 Oct 4. Mult Scler Relat Disord. 2019. PMID: 31610404
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study.
Maniscalco GT, Saccà F, Lanzillo R, Annovazzi P, Baroncini D, Binello E, Repice A, Perini P, Clerico M, Mataluni G, Bonavita S, La Gioia S, Gutierrez LP, Laroni A, Frau J, Cocco E, Torri Clerici V, Zarbo IR, Sartori A, Signoriello E, Rasia S, Cordioli C, Stromillo ML, Cerqua R, Pontecorvo S, Di Sapio A, Grasso R, Barone S, Lavorgna L, Barrilà C, Landi D, Russo CV, Frigeni B, Ippolito D, Turano G, Carmisciano L, Sormani MP, Signori A. Maniscalco GT, et al. Among authors: frau j. Mult Scler Relat Disord. 2020 Jul;42:102059. doi: 10.1016/j.msard.2020.102059. Epub 2020 Mar 16. Mult Scler Relat Disord. 2020. PMID: 32208344
217 results